Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hervé Hoppenot
Marketing
Incyte's eczema cream Opzelura off to 'very successful' launch
Incyte CEO has projected the JAK inhibitor could reach $1.5 billion in U.S. eczema sales alone despite a classwide boxed warning.
Angus Liu
Feb 8, 2022 11:40am
Incyte CEO: Established relationships key to COVID drug launches
Jan 15, 2021 9:36am
Incyte hands CEO Hoppenot a 36% pay hike despite R&D setbacks
Mar 20, 2018 10:40am
Merck, BMS racing again with new Incyte combos
Apr 3, 2017 9:07am